CIK: 0001637359 · Show all filings
Period: Q2 2020 (← Previous) (Next →)
Filing Date: Aug 17, 2020
Total Value ($000): $365,744 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| REPL | Replimune Group | 5,344,971 | $132,161 | 36.1% | $17.40 | +1.6% | Common Stock | 76029N106 |
| — | Morphic Holding | 2,975,582 | $80,489 | 22.0% | $19.82 | — | Common Stock | 61775R105 |
| GOSS | Gossamer Bio | 3,320,608 | $43,168 | 11.8% | $20.85 | -39.7% | Common Stock | 38341P102 |
| ARQT | Arcutis Biothereapeutics | 844,680 | $25,543 | 7.0% | $26.87 | +7.6% | Common Stock | 03969K108 |
| IMUX | Immunic | 1,371,494 | $16,623 | 4.5% | $13.14 | -22.6% | Common Stock | 4525EP101 |
| — | Paratek Pharmaceuticals | 2,602,739 | $13,586 | 3.7% | $34.18 | — | Common Stock | 699374302 |
| — | ESSA Pharma | 1,497,448 | $9,284 | 2.5% | $3.14 | — | Common Stock | 29668H708 |
| TRVI | Trevi Therapeutics | 1,375,907 | $9,053 | 2.5% | $8.20 | -57.1% | Common Stock | 89532M101 |
| BEAM | Beam Therapeutics | 302,821 | $8,479 | 2.3% | $21.73 | -0.8% | Common Stock | 07373V105 |
| — | Cidara Therapeutics | 2,005,249 | $7,399 | 2.0% | $5.64 | — | Common Stock | 171757107 |
| — | ObsEva | 999,364 | $5,886 | 1.6% | $9.76 | — | Common Stock | H5861P103 |
| — | FibroGen | 130,646 | $5,295 | 1.4% | $27.34 | — | Common Stock | 31572Q808 |
| — | Jounce Therapeutics | 529,965 | $3,657 | 1.0% | $21.99 | — | Common Stock | 481116101 |
| — | Prevail Therapeutics | 187,538 | $2,794 | 0.8% | $13.20 | — | Common Stock | 74140Y101 |
| — | Pieris Pharmaceuticals | 750,741 | $2,327 | 0.6% | $1.83 | — | Common Stock | 720795103 |